v3.26.1
Revenue - Additional Information (Details) - USD ($)
1 Months Ended
Feb. 29, 2024
Mar. 31, 2026
Dec. 31, 2025
Mar. 31, 2025
Dec. 31, 2024
Revenue Recognition          
Billed contracts receivable   $ 19,100,000 $ 95,600,000    
Unbilled contracts receivable   4,200,000 10,800,000    
Allowance for credit losses   0   $ 0  
Amount of transaction price not yet satisfied   600,000,000      
Deferred revenue   448,045,000 498,996,000 517,891,000 $ 1,121,886,000
Claim related to performance obligation       $ 23,000,000.0  
Other current liabilities   132,449,000 137,778,000    
Other non-current liabilities   193,244,000 239,068,000    
Current deferred revenue   88,772,000 140,053,000    
Noncurrent deferred revenue   359,273,000 $ 358,943,000    
Australia Revenue Agency Member          
Revenue Recognition          
Deferred revenue refund   92,500,000      
Noncurrent deferred revenue   85,400,000      
Settlement Agreement          
Revenue Recognition          
Litigation settlement, expense $ 400,000,000        
Grants receivable 225,000,000 225,000,000.0      
Litigation settlement, amount awarded to other party 75,000,000        
Other current liabilities   80,000,000.0      
Other non-current liabilities   160,000,000.0      
Gavi Advance Purchase Agreement- COVAX Facility          
Revenue Recognition          
Collaborative agreement, upfront payment amount 700,000,000        
Australian APA          
Revenue Recognition          
Advanced payment paid   31,000,000      
Current deferred revenue   $ 48,400,000      
Gavi Settlement Agreement          
Revenue Recognition          
Litigation settlement, expense $ 80,000,000